266 related articles for article (PubMed ID: 33790563)
21. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients.
Pizzuti AG; Murray EY; Wagner JL; Gaul DA; Bland CM; Jones BM
Infect Dis Ther; 2020 Dec; 9(4):1043-1053. PubMed ID: 33083894
[TBL] [Abstract][Full Text] [Related]
22. Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios.
Cacopardo B; Cattaneo D; Cortese F; Di Luca M; Falcone M; Marchetti G; Tascini C; Tiseo G; Venditti M
Expert Rev Anti Infect Ther; 2022 Jul; 20(7):997-1004. PubMed ID: 35353020
[TBL] [Abstract][Full Text] [Related]
23. Off-label use of dalbavancin in children: a case series.
Gamell A; Velasco-Arnaiz E; López-Ramos MG; Ríos-Barnés M; Simó-Nebot S; Fumadó V; Noguera-Julián A; Fortuny C
J Antimicrob Chemother; 2024 Jul; ():. PubMed ID: 38958260
[TBL] [Abstract][Full Text] [Related]
24. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
25. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
Gatti M; Andreoni M; Pea F; Viale P
Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
[TBL] [Abstract][Full Text] [Related]
26. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context.
De Nicolò A; Stroffolini G; Antonucci M; Mula J; De Vivo ED; Cusato J; Palermiti A; Cariti G; Di Perri G; Corcione S; De Rosa FG; D'Avolio A
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680409
[TBL] [Abstract][Full Text] [Related]
28. Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
Zhanel G; Silverman M; Malhotra J; Baxter M; Rahimi R; Irfan N; Girouard G; Dhami R; Kucey M; Stankus V; Schmidt K; Poulin S; Connors W; Tascini C; Walkty A; Karlowsky J
J Glob Antimicrob Resist; 2024 Jun; ():. PubMed ID: 38908823
[TBL] [Abstract][Full Text] [Related]
29. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
[TBL] [Abstract][Full Text] [Related]
30. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
[TBL] [Abstract][Full Text] [Related]
31. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.
Juul JJ; Mullins CF; Peppard WJ; Huang AM
Ther Clin Risk Manag; 2016; 12():225-32. PubMed ID: 26937194
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study.
Courjon J; Senneville E; Illes HG; Pavese P; Boutoille D; Daoud FC; Dunkel N; Tattevin P
Int J Antimicrob Agents; 2023 Oct; 62(4):106945. PubMed ID: 37543122
[TBL] [Abstract][Full Text] [Related]
33. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
[TBL] [Abstract][Full Text] [Related]
34. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
[TBL] [Abstract][Full Text] [Related]
35. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
[TBL] [Abstract][Full Text] [Related]
36. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Scott LJ
Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
[TBL] [Abstract][Full Text] [Related]
37. Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience.
Scarano SM; Bruzzese E; Poeta M; Del Bene M; Guarino A; Lo Vecchio A
Antibiotics (Basel); 2024 Apr; 13(4):. PubMed ID: 38667003
[TBL] [Abstract][Full Text] [Related]
38. Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin.
Loupa CV; Lykoudi E; Meimeti E; Moisoglou I; Voyatzoglou ED; Kalantzi S; Konsta E
Med Arch; 2020 Jun; 74(3):243-245. PubMed ID: 32801445
[TBL] [Abstract][Full Text] [Related]
39. Dalbavancin: a new lipoglycopeptide antibiotic.
Bailey J; Summers KM
Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
[TBL] [Abstract][Full Text] [Related]
40. Dalbavancin: a review for dermatologists.
Scheinfeld N
Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
